Loading...
Loading...
DVAX| Name | Value |
|---|---|
| Revenues | 73.8M |
| Cost of Revenue | 12.0M |
| Gross Profit | 61.8M |
| Operating Expense | 55.8M |
| Operating I/L | 6.1M |
| Other Income/Expense | 8.8M |
| Interest Income | 9.2M |
| Pretax | 14.9M |
| Income Tax Expense | 3.5M |
| Net Income/Loss | 11.4M |
Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of vaccines. Its flagship product, HEPLISAV-B, is a hepatitis B vaccine designed to prevent infection caused by all known subtypes of hepatitis B virus in individuals aged 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation generates revenue through the sale of its vaccines and adjuvant, as well as through collaboration and sublicense agreements with other pharmaceutical companies.
